Aarti Pharmalabs Ltd Submits BRSR for FY 24-25 with 57.27% Exports Contribution

Aarti Pharmalabs Ltd, a pharmaceuticals and nutraceuticals manufacturer, has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2024-25. The company's core business includes the development of Active Pharmaceutical Ingredients (API) and New Chemical Entities (NCE), API intermediates, Regulatory Starting Materials (RSM), Basic Starting Materials, Key Building Blocks, and Xanthine Derivatives. Aarti Pharmalabs contributes to both regulated and non-regulated markets with exports accounting for approximately 57.27% of its total turnover. The company caters to a diverse spectrum of B2B customers, including global pharmaceutical innovators and generic manufacturers, nutraceutical, food & beverage companies, agrochemical manufacturers, polymer and plastics companies, and dye and pigment producers.